Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool July 22, 2011 Evan Niu	Clorox to Icahn: "It's Not You, It's Me" Clorox announces that its board has unanimously rejected Icahn's unsolicited bid to acquire the company.
The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool April 21, 2005 Timothy M. Otte	Brawling at Blockbuster What's with this war of words between corporate raider Carl Icahn and Blockbuster management?
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
The Motley Fool May 12, 2005 Rick Aristotle Munarriz	Icahn's Blockbuster Move Billionaire investor Carl Icahn wins a spot on the Blockbuster board, but that's only the beginning. Blockbuster has really been trying the patience of its shareholders lately.
The Motley Fool May 5, 2005 Rick Aristotle Munarriz	Make It a Blockbuster Fight Blockbuster and Carl Icahn are just days away from a battle at the company's shareholder meeting. Given Blockbuster's deteriorating financials and the sector's quickly changing landscape, it's hard to value the company based on its future prospects.
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool March 23, 2005 Stephen D. Simpson	Kerr-McGee Gets the Message Will this deepwater driller, a historical underachiever, succeed in acting in shareholders' best interests?
The Motley Fool April 15, 2005 Tom Taulli	Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
National Real Estate Investor December 4, 2002 Parke Chapman	Investor now holds 6.9% stake in Insignia Carl Icahn now holds a 6.9% stake in real estate operator Insignia Financial Group Inc.
The Motley Fool May 31, 2005 Tom Taulli	The Icahn Effect Carl Icahn has spread fear throughout corporate boardrooms. Now hedge fund Relational Investors looks like an Icahn wannabe.
The Motley Fool July 23, 2008 Rick Aristotle Munarriz	Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane?
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool September 29, 2011 Evan Niu	Does HP Need a Poison Pill? HP may have tapped Goldman Sachs to defend itself against activist investors.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool September 1, 2005 Steven Mallas	Time for Time Warner? Time Warner has seen some interesting times lately. Should you buy the stock?
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool October 25, 2006 Brian Lawler	Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn.
The Motley Fool August 12, 2005 Tom Taulli	Big Game Hunter As usual, Carl Icahn has a good sense of shifts in Corporate America. By taking a position on Time Warner, he's certainly going to be heard. And divvying up some of the assets may produce higher returns for shareholders as well.
The Motley Fool February 8, 2006 Rick Aristotle Munarriz	Time Warner's Splitting Headache Carl Icahn's investment banker suggests Time Warner break up into four pieces. But the company is doing its part to make investors know that it's not asleep at the wheel. With every quarterly improvement, Icahn's voice is likely to grow that much quieter.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool August 1, 2008 Brian Lawler	Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?
The Motley Fool June 22, 2011	Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011.
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
The Motley Fool October 12, 2005 W.D. Crotty	Icahn's Case for Time Warner Carl Icahn issues an open letter to shareholders pushing for change on the company's board. Investors should realize, though, that just because Icahn is around, that doesn't mean their shares will automatically go up.
The Motley Fool January 12, 2006 Rich Duprey	Will the SEC Trim the Hedges? As hedge funds are immersing themselves even more in mergers and acquisitions, a field that is fast approaching $1 trillion a year, it's not surprising that they will now also find themselves under closer scrutiny by regulators.
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool February 17, 2006 Rick Aristotle Munarriz	A Time for Peace Carl Icahn appears to have come to a truce with Time Warner over his breakup plans. However, a significant show of shareholders siding with Icahn's nominees may also force Time Warner to take a harder look at why it can't seem to get its stock out of the high teens.
The Motley Fool February 4, 2010 Stephen Mauzy	My Favorite Investor I think that for most investors, the Icahn approach of buying distressed companies at very good prices even surpasses the Warren Buffett approach of buying good companies at fair prices.
The Motley Fool August 22, 2011 Dan Radovsky	Should Icahn's Interest in Clorox Perk Yours? Does corporate raider Carl Icahn want to clean Clorox's house for himself, or does he just want to flip it for a quick profit?
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool March 30, 2011 Anders Bylund	Mentor Could Use Some Guidance Is the company looking to preserve shareholder interest or management paychecks?
The Motley Fool November 30, 2005 Rick Aristotle Munarriz	I Think Icahn, Time Warner Despite the market's interest in Time Warner's online operations, billionaire investor Carl Icahn still believes that more can be done to improve shareholder value.
InternetNews January 30, 2007 Ed Sutherland	Icahn Has Motorola in His Sites News Wall Street trader Carl Icahn wants a spot on Motorola's board sent tongues wagging and stock prices up.
The Motley Fool May 16, 2008 Mac Greer	Fool Video: Icahn Bares His Teeth, Craig's Cyst, and 5 Stocks Approaching Greatness Can Craigslist delete eBay? Will Icahn deliver for Microsoft? These questions are discussed in this video.
The Motley Fool November 8, 2005 Rich Duprey	Fairmont's Fair Game for Icahn Financier takes a stake in the luxury resort chain Fairmont Hotels & Resorts to maximize undervalued assets. These plans should really come as no surprise to Fairmont investors.
The Motley Fool September 2, 2005 Rick Aristotle Munarriz	Blockbuster Keeps the Change Since corporate raider Carl Icahn came aboard, a sense of financial sensibility has begun to emerge at Blockbuster. The struggling movie-rental giant eliminates its quarterly dividend.
The Motley Fool December 15, 2010 Toby Shute	This Corporate Raider Hasn't Lost His Touch Has Carl Icahn outsmarted Blackstone with his bid for utility company Dynegy? The tentative answer today appears to be yes.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
BusinessWeek October 29, 2007 Hamm & Grover	Tech Gets the Icahn Treatment Carl Icahn is shaking up the landscape in Silicon Valley as companies' revenue growth slows.
The Motley Fool February 17, 2010 Anders Bylund	Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney?
The Motley Fool April 16, 2009 Brian Orelli	Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders?